AI Article Synopsis
Article Abstract
Background: There may be a difference in the number of articles about COVID-19 and SARS-CoV-2 between low- and middle-income countries (LMICs) and high-income countries (HICs).
Methods: We analyzed authors' affiliations from 36 432 articles related to COVID-19 and SARS-CoV-2. We introduced logarithmic density and compared the number of articles and logarithmic density of LMICs with those of HICs.
Results: The number of articles and the logarithmic density of LMICs were lower than those of HICs (p<0.0001 for both).
Conclusions: There was a disparity in the number of articles related to COVID-19 and SARS-CoV-2 between LMICs and HICs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665544 | PMC |
| http://dx.doi.org/10.1093/inthealth/ihaa088 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents.
Hum Vaccin Immunother
December 2025
Research and Development, Infectious Disease, Moderna, Inc., Cambridge, MA, USA.
Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12-17 years), with and without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose mRNA-1273 100-µg primary series in the TeenCOVE trial (NCT04649151) were offered the mRNA-1273 50-μg booster. Primary objectives included safety and inference of effectiveness by establishing noninferiority of neutralizing antibody (nAb) responses after the booster compared with the nAb post-primary series of mRNA-1273 among young adults in COVE (NCT04470427).
View Article and Find Full Text PDFBackground: Molnupiravir (MOV) is an orally bioavailable ribonucleoside with antiviral activity against all tested SARS-CoV-2 variants. We describe the demographic, clinical, and treatment characteristics of non-hospitalized Danish patients treated with MOV and their clinical outcomes following MOV initiation.
Method: Among all adults (>18 years) who received MOV between 16 December 2021 and 30 April 2022 in an outpatient setting in Denmark, we summarized their demographic and clinical characteristics at baseline and post-MOV outcomes using descriptive statistics.
My back hurts! Did you have COVID-19 infection?
Agri
January 2025
Department of Algology, Ministry of Health Ankara Etlik City Hospital, Ankara, Türkiye.
Pain may be an early symptom of COVID-19 infection, most commonly seen as myalgia and headache. However, atypical presentations such as abdominal pain and leg pain can also be observed. We present seven cases of COVID-19 treated for pain.
View Article and Find Full Text PDFSelf-reported perceptions of adults with diabetes regarding their care and health in the time of COVID-19 pandemic in a Swiss region: a cross-sectional study.
Swiss Med Wkly
December 2024
Center for Primary Care and Public Health (Unisanté), Department of Epidemiology and Health Systems, University of Lausanne, Lausanne, Switzerland.
Aim: To assess the perceptions of adults with diabetes regarding their care and health during the COVID-19 pandemic in the canton of Vaud, Switzerland.
Methods: Cross-sectional data was analysed from the 2021 follow-up questionnaire of the CoDiab-VD survey, a cohort of adults living with diabetes in the canton of Vaud. Various aspects of diabetes care and issues relating to the COVID-19 pandemic were assessed.
Antimicrobial and Antiproliferative Properties of 2-Phenyl-N-(Pyridin-2-yl)acetamides.
Chem Biol Drug Des
January 2025
Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
Infectious diseases, including bacterial, fungal, and viral, have once again gained urgency in the drug development pipeline after the recent COVID-19 pandemic. Tuberculosis (TB) is an old infectious disease for which eradication has not yet been successful. Novel agents are required to have potential activity against both drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis (Mtb), the causative agent of TB.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!